Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2022-02-04 Annual Report
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) and 'Lagebericht' (Management Report) for Formycon AG for the fiscal year 2020. It contains detailed business model descriptions, project development updates, and economic analysis. As it is a comprehensive annual financial report, it falls under the 10-K category. FY 2020
2022-02-04 German
MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region
Regulatory Filings Classification · 95% confidence The document is a press release dated December 14, 2021, announcing a commercialization partnership between Formycon AG (via its licensee Bioeq AG) and MS Pharma for a biosimilar candidate (FYB201) in the MENA region. It uses keywords like 'Press Release', 'Alliance/Agreement', and discusses business development and licensing, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it is a specific business announcement disseminated via a news service (DGAP), and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for corporate news announcements that are not otherwise specified. Given the content is a strategic business update, RNS is the most appropriate general classification.
2021-12-14 English
Formycon and Scientists from TUM publish new Data on broadly effective SARS-CoV-2 antiviral Drug FYB207
Investor Presentation Classification · 90% confidence The document is a press release dated December 9, 2021, announcing the publication of new *in vitro* data regarding the SARS-CoV-2 antiviral drug FYB207 in the journal 'Antiviral Research'. It details scientific findings, mentions ongoing preclinical studies, and provides an expected timeline for clinical trials. It is not a formal regulatory filing like a 10-K, nor is it a brief announcement of a report (RPA/RNS) as it contains substantial substantive information about the research results. Since it is a detailed announcement of scientific/research progress and study results, it best fits the category for Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if no other category fits well. Given the focus on presenting new data and development progress to the market, 'Investor Presentation' (IP) is a strong candidate, although it is structured as a press release. However, looking at the definitions, this is a scientific/research update announcement, which often accompanies or precedes an Investor Presentation. Since it is a detailed press release announcing study results and future plans, and not a formal financial report, it is closest to an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the context of a company announcing scientific breakthroughs and development progress, 'Investor Presentation' (IP) captures the intent better than the generic 'RNS', although it is structured as a DGAP news release. If the content were purely regulatory or miscellaneous, RNS would be used. Since it is substantive news about product development, IP is selected as the best fit among the specific options for non-financial reports.
2021-12-09 English
Formycon Reports its Nine-Month Figures for 2021
Earnings Release Classification · 100% confidence The document is titled "Formycon Reports its Nine-Month Figures for 2021" and explicitly discusses turnover, EBITDA, net results, and forecasts for the first nine months of the fiscal year 2021. This content structure—a press release detailing financial performance for a period shorter than a full year (nine months)—is characteristic of an Interim/Quarterly Report announcement. Although it is presented as a press release (often associated with ER), the depth of the nine-month figures and the focus on the period's results align best with the definition of an Interim Report (IR). It is not a full Annual Report (10-K) or just a brief Earnings Release (ER) highlighting only key metrics; it provides substantial financial detail for the nine-month period. 9M 2021
2021-11-09 English
Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
Regulatory Filings Classification · 100% confidence The document is titled 'News Details' and is explicitly labeled as a 'Press Release' dated October 19, 2021. It announces a 'Collaboration and License Agreement' between Formycon and SCG Cell Therapy regarding a COVID-19 drug. This type of announcement, detailing a strategic business development (alliance/agreement), does not fit the specific financial reporting categories like 10-K, ER, or IR. Since it is a general corporate announcement disseminated via DGAP (a service often used for regulatory news but here used for a press release about a business deal), and it doesn't fit any other specific category (like M&A (TAR) or Capital Change (CAP)), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate news that isn't a core financial report or specific event filing. The length (8800 chars) is substantial enough that it is the primary content, not just an announcement of content.
2021-10-19 English
Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Regulatory Filings Classification · 95% confidence The document is labeled as 'Ad-hoc' and contains an 'Insider information acc. to Article 17 MAR' disclosure. It announces a specific corporate event: a 'Collaboration and License Agreement' regarding a drug candidate (FYB207). This type of announcement, detailing a significant business development (alliance, licensing deal, potential future payments), does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). It is a general regulatory announcement concerning a material event. Since it is not a standard financial report, a management discussion, or a specific shareholder vote result, the most appropriate fallback category for a significant, non-standard corporate disclosure disseminated via regulatory channels (DGAP/EQS) is 'Regulatory Filings' (RNS). The document length (5776 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication.
2021-10-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.